GenProfile AG

GENPROFILE

PHARMACEUTICALS, PARTICULARLY DEVELOPED ON THE BASIS OF BIOTECHNOLOGICAL METHODS, PARTICULARLY FOR THE TREATMENT OF DIABETES I OR II; ARTERIOSCLEROSIS; HEART ATTACKS; HEART FAILURES; STROKES; PARKINSON'S DISEASE; ALZHEIMER'S DISEASE; LEUKEMIA; SOLID TUMORS, PARTICULARLY BRAIN, LIVER, PANCREAS, LUNG OR INTESTINAL TUMORS; INFECTIOUS DISEASES, PARTICULARLY BACTERIAL, VIRAL OR PROTOZOOLOGICAL INFECTIOUS DISEASES, PARTICULARLY TUBERCULOSIS, HIV, MALARIA, LEISHMANIASIS; AUTOMIMMUNIE DISEASES, PARTICULARLY TEN, RHEUMATIC ARTHRITIS, LUPUS ERYTHEMATOSUS, MULTIPLE SCLEROSIS; NEUROLOGICAL DISORDERS; METABOLIC DISORDERS; DISORDERS BASED ON PATHOLOGICAL INFLAMMATORY REACTIONS;GEN PROFILE; GENERATE PROFILE;BUSINESS MANAGEMENT;COMPUTER SERVICES, NAMELY, PROVIDING DATABASES FEATURING BIOLOGICAL INFORMATION INCLUDING RISK FACTORS FOR THE MANIFESTATION OF COMMON DISEASES OR FOR THE MANIFESTATION OF POLYMORPHISM, AND FOR PASSING ON THIS DATA TO THIRD PARTIES; DEVELOPMENT FOR OTHERS OF PHARMACEUTICALS AND PHARMACEUTICALLY ACTIVE SUBSTANCES, PARTICULARLY DEVELOPED ON THE BASIS OF BIOTECHNOLOGICAL METHODS; PREPARING AND PERFORMING CLINICAL STUDIES OF PHARMACEUTICALS;